Particle.news
Download on the App Store
5 ARTICLES
·
last mo.

Biontech, Curevac Agree on $740 Million Covid-19 Vaccine Patent Settlement

Featuring a 1 percent US royalty retroactive to January 2025 plus expanded mRNA licensing rights, the agreement paves the way for Biontech’s planned year-end takeover.

Image
Die Übernahme der Tübinger durch Biontech soll wie geplant bis Jahresende abgeschlossen werden.
Image
Image

Overview

  • Biontech will make $740 million in upfront payments, split equally between Curevac and GlaxoSmithKline.
  • The deal imposes a 1 percent royalty on US Covid-19 vaccine revenues dating back to January 1, 2025.
  • Curevac grants Biontech and Pfizer a non-exclusive US license for mRNA-based Covid-19 and influenza products, with global rights to follow after the acquisition.
  • A significant share of the settlement funds is designated to return to Biontech’s treasury once the takeover closes.
  • Both companies confirm the acquisition remains on schedule for year-end completion and insist the settlement is not an admission of liability.